AndrewXiuxaunZhuMD

Oncology • Boston, MA

Associate Professor of Medicine, Massachusetts General Hospital

Join to view full profile

Dr. Zhu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zhu's full profile

Already have an account?

Office
55 Fruit St
Yawkey 7e
Boston, MA 02114
Phone+1 617-724-6193

Fax+1 617-724-1137

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
Yale-New Haven Medical CenterResidency, Internal Medicine, 1995 - 1997
University of MinnesotaInternship, Internal Medicine, 1994 - 1995
Beijing Medical UniversityClass of 1982

Certifications & Licensure

MA State Medical License 2000 - 2025

Clinical Trials

Epirubicin and Thalidomide in Treating Patients With Liver Cancer Start of enrollment: 2001 Dec 01
Completed
Phase 2
Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma Start of enrollment: 2005 Jan 01
Completed
Phase 2
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma Start of enrollment: 2004 Apr 01
Completed
Phase 2
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Start of enrollment: 2004 Dec 01
Completed
Phase 2
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Start of enrollment: 2006 May 01
Completed
Phase 2
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer Start of enrollment: 2006 Jul 01
Terminated
Phase 1, Phase 2
SU011248 in Advanced Hepatocellular Carcinoma Start of enrollment: 2006 Apr 01
Completed
Phase 2
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer Start of enrollment: 2009 May 01
Terminated
Phase 2
RAD001 in Advanced Hepatocellular Carcinoma Start of enrollment: 2007 Aug 01
Completed
Phase 1, Phase 2
Sorafenib + mFOLFOX for Hepatocellular Carcinoma Start of enrollment: 2013 Jan 01
Completed
Phase 2
HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) Start of enrollment: 2013 May 01
Terminated
Phase 4
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 1
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Start of enrollment: 2014 Jul 23
Terminated
Phase 2
Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Start of enrollment: 2015 Apr 01
Completed
Phase 2
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Start of enrollment: 2015 Jul 20
Completed
Phase 3
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer Start of enrollment: 2021 Jul 28
Recruiting
Join now to see all

Publications & Presentations

PubMed

772 citations
Immunotherapies for hepatocellular carcinoma.
Josep M. Llovet, Florian Castet, Mathias Heikenwalder, Mala K. Maini, Vincenzo Mazzaferro
Nature Reviews. Clinical Oncology. 2021-11-11
252 citations
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
Bryan C. Fuchs, Tsutomu Fujii, Jon D. Dorfman, Jonathan M. Goodwin, Andrew X. Zhu
Cancer Research. 2008-04-01
187 citations
Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Alphonse E. Sirica, Gregory J. Gores, John D. Groopman, Florin M. Selaru, Mario Strazzabosco
Hepatology. 2019-04-01

Journal Articles

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Andrew Zhu, MD, Frontiers in Immunology
A Phase II and Biomarker Study of Sorafenib Combined with FOLFOX in Patients with Advanced Hepatocellular Carcinoma (HCC)
Hui Zheng, Rakesh K Jain, Lipika Goyal, Andrew X Zhu, Clinical Cancer Research

Lectures

REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular c...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D DayApril 19th, 2022
I-mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual MeetingMarch 9th, 2022
I-mab Receives FDA Orphan Drug Designation for Its Novel Claudin 18.2 X 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric CancerMarch 3rd, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member